Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

As autumn arrives and the harvest season begins, China and France are joining hands to open a new chapter of collaboration. Hosted by the Chinese Medical Doctor Association and the Chinese Society for Immunology, and organized by the Hematology Physicians Branch of the Chinese Medical Doctor Association and the National Clinical Research Center for Hematologic Diseases–Institute of Hematology, Peking University, the 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Olive Daniel of the Institut Paoli-Calmettes in Marseille, who shared in-depth insights into the key pathways for translating immune-regulatory research from basic science to clinical application, the current status and challenges of translational medicine, and the complementary strengths and prospects for collaboration between China and France in hematology and immunology.
Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology

Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology

The 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of China-France exchanges in hematology, this year's conference further expanded into the intersection of hematology and immunology, bringing together renowned experts in hematology and immunology from China and France to explore cutting-edge developments and exchange academic perspectives. On this occasion, Oncology Frontier – Hematology Frontier interviewed Professor Bingcheng Liu of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, who provided an in-depth analysis of the exploration of B-cell acute lymphoblastic leukemia (B-ALL) from personalized immunity to precision immunotherapy, including breakthrough advances in B-ALL immunotherapy, precision stratification strategies, and the optimal sequencing and integration of different immunotherapeutic approaches.
CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights

CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights

The 29th Chinese Society of Clinical Oncology (CSCO) Annual Meeting was held in Jinan from September 16 to 19, 2026, bringing together leading oncology experts from around the world to explore pathways for innovation and advancement in precision cancer care. Professor Franco Cavalli, President of the International Conference on Malignant Lymphoma (ICML) and Professor at the Oncology Institute of Southern Switzerland in Bellinzona, was invited to attend the meeting and deliver a special presentation. As an internationally renowned expert who has devoted decades to oncology, Professor Cavalli has witnessed more than 30 years of transformation in Chinese oncology since his first visit to China in 1989. In an interview with Oncology Frontier – Hematology Frontier, he reflected on his longstanding exchanges and collaboration with the Chinese oncology community, shared key advances and future directions in extranodal lymphoma, and previewed the major topics to watch at ICML 2027.
Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

The Pujiang Prostate Cancer Academic Conference was recently held in Shanghai. Under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration,” the conference provided a high-level platform for academic exchange, focusing on key topics including early screening and precision diagnosis of prostate cancer, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care systems. By fostering deeper integration between clinical practice and cutting-edge research, the conference aimed to further advance the standard of prostate cancer care in China.
2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies

2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies

The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. The rapid development of antibody–drug conjugates (ADCs) and immunotherapy is moving the treatment of urothelial carcinoma beyond later-line advanced disease to first-line treatment, the perioperative setting, and even non-muscle-invasive disease. At the same time, the clinical introduction of ADCs with multiple targets and payloads has raised new challenges, including treatment sequencing, cross-resistance, and cumulative toxicity. Oncology Frontier – UroStream invited Professor Xiaojie Bian of Fudan University Shanghai Cancer Center for an interview to discuss the earlier use of ADCs, sequencing strategies, perioperative investigations, and comprehensive safety management throughout the treatment continuum.
CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing

CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing

Precise suturing is a key foundation for high-quality reconstruction in minimally invasive surgery. During laparoscopic radical prostatectomy, vesicourethral anastomosis tests the surgeon's ability to control needle-holding angles and needle trajectories, while directly affecting procedural stability and reproducibility. In this interview, Oncology Frontier – UroStream invited Professor Zhenghua Ju of Fujian Cancer Hospital to discuss the technical challenges of laparoscopic vesicourethral anastomosis, the evolution of the 360° suturing theory into the “Three Fundamental Principles of Surgical Suturing,” and the clinical value of standardized dissemination and training.
Professor Hongkai Wang: Advancing Robotic Radical Prostatectomy Through Technical Innovation to Preserve Both Cancer Control and Function | Pujiang Prostate Cancer Academic Conference

Professor Hongkai Wang: Advancing Robotic Radical Prostatectomy Through Technical Innovation to Preserve Both Cancer Control and Function | Pujiang Prostate Cancer Academic Conference

The 2026 Pujiang Prostate Cancer Academic Conference was successfully held in Shanghai under the central theme of “Standardization, Precision Breakthroughs, Chinese Innovation, and Global Collaboration.” The conference aimed to promote the standardized diagnosis and treatment of prostate cancer in China while advancing key technological innovations. Following the meeting, Oncology Frontier – UroStream invited Professor Hongkai Wang of Fudan University Shanghai Cancer Center to discuss recent innovations in robotic radical prostatectomy, balancing oncological control with functional preservation, and the development of domestically developed surgical robots.
CACA GU | Professor Xiang Li: From Clinical Risk Stratification to Molecular Subtyping—A New Pathway to Precision Treatment for Advanced Renal Cell Carcinoma

CACA GU | Professor Xiang Li: From Clinical Risk Stratification to Molecular Subtyping—A New Pathway to Precision Treatment for Advanced Renal Cell Carcinoma

Treatment decisions for advanced renal cell carcinoma (RCC) are shifting from traditional clinical risk stratification toward precision classification based on molecular characteristics. What is the scientific rationale behind this trend? Which key molecular biomarkers hold the greatest promise for guiding treatment selection and sequencing? And what are the major obstacles to translating scientific discoveries in precision medicine into clinical practice?
CACA GU | Professor Zhuowei Liu: Advancing Standardized Urologic Oncology Care from Prevention to Comprehensive Management

CACA GU | Professor Zhuowei Liu: Advancing Standardized Urologic Oncology Care from Prevention to Comprehensive Management

Approximately 101,000 new cases of bladder cancer are diagnosed annually in China, making it the 11th most common malignancy. The disease is more prevalent in southern China than in the north, and its incidence is trending toward younger age groups. Meanwhile, high-risk localized or locally advanced prostate cancer carries a substantial risk of biochemical recurrence and distant metastasis, and local treatment alone is often insufficient to address the full spectrum of clinical needs.
CSCO 2026 | Professor Xinan Sheng: Clinical Insights from 3.5-Year Follow-Up of the EV-302 Trial—Long-Term Survival Benefits and Treatment Continuity

CSCO 2026 | Professor Xinan Sheng: Clinical Insights from 3.5-Year Follow-Up of the EV-302 Trial—Long-Term Survival Benefits and Treatment Continuity

Platinum-based chemotherapy has historically been the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), but long-term survival outcomes have remained poor. There is an urgent clinical need for first-line regimens that offer high efficacy and sustained disease control. The EV-302 trial directly compared enfortumab vedotin plus pembrolizumab with standard platinum-based chemotherapy. Earlier interim analyses demonstrated the significant superiority of the combination over chemotherapy, reshaping international treatment guidelines.